Acute agitation management commonly aligns with emergency psychiatry consensus and ED agitation pathways
Antipsychotics and benzodiazepines supported by broad clinical trial and practice guideline evidence
Class-style recommendation mapping for internal use
Class I
If imminent danger, rapid tranquilization with monitoring and least restrictive approach
Class IIa
Antipsychotic monotherapy for acute mania without contraindications
Class IIb
Benzodiazepine adjunct when agitation persists or catatonia suspected
ACEP-style mapping for internal use
ACEP Level B
Structured de-escalation and pharmacologic sedation protocols reduce agitation-related harm in ED systems
ACEP Level C
Routine neuroimaging not indicated without red flags
Special Populations
Pregnancy
Pregnancy considerations
Risk-benefit framework
Untreated mania and depression maternal and fetal risks
Medication teratogenicity risks
Medication safety highlights
Valproate avoidance due to high teratogenic risk
Lithium risk discussion and trimester-specific specialist guidance
Antipsychotics commonly used when benefits outweigh risks
Care coordination
Obstetrics involvement for confirmed pregnancy
Perinatal psychiatry referral pathway
Geriatric
Older adult considerations
Delirium prevalence and medical mimics
Lower threshold for medical workup
Medication adverse effect sensitivity
Medication strategy adjustments
Lower starting doses and slower titration
Anticholinergic minimization
Monitoring
Orthostasis and falls risk
QTc and electrolyte monitoring for antipsychotics
Pediatrics
Pediatric and adolescent considerations
Diagnostic caution
Irritability differential with ADHD and disruptive disorders
Trauma and substance use assessment
Medication dosing
Weight-based dosing per pediatric psychiatry protocols
Increased sensitivity to EPS and metabolic effects
Safety
Family involvement and supervision planning
School and social support coordination
Background
Epidemiology
Epidemiology overview
Bipolar I disorder
Lifetime prevalence commonly around 1%
Similar prevalence across sexes in many studies
Bipolar II disorder
Lifetime prevalence commonly around 1% to 2%
Often first recognized during depressive episodes
Age of onset
Often late adolescence to early adulthood
Earlier onset associated with higher recurrence risk
Pathophysiology
Pathophysiology concepts
Neurotransmitter and circuit dysregulation
Dopamine signaling changes in mania models
Glutamate and GABA imbalance hypotheses
Circadian rhythm disruption
Sleep loss as trigger and amplifier
Social rhythm instability contribution
Genetic and environmental interplay
Heritability signal in family and twin studies
Stress sensitization and episode recurrence risk
Therapeutic Considerations
Treatment principles
Acute mania
Antipsychotics for rapid symptom control
Mood stabilizers for relapse prevention linkage
Bipolar depression
Avoid antidepressant monotherapy due to switching risk
Evidence-supported agents include quetiapine and lurasidone in many guidelines
Maintenance
Mood stabilizers reduce recurrence risk
Psychotherapy improves adherence and early relapse detection
Medication monitoring burden
Lithium renal and thyroid monitoring
Valproate hepatic and hematologic monitoring
Antipsychotic metabolic monitoring
Patient Discharge Instructions
copy discharge instructions
Discharge instructions
Diagnosis and expectations
Bipolar mood episode symptoms can fluctuate over days to weeks
Sleep restoration and medication adherence reduce relapse risk
Medication guidance
Take medications exactly as prescribed
Avoid alcohol and recreational drugs
Do not stop medications abruptly without clinician guidance
Sleep and routine
Regular sleep schedule with protected bedtime
Reduce caffeine and stimulants
Return to ED now if
Thoughts of self-harm or harming others
Feeling unable to stay safe
New hallucinations or severe paranoia
No sleep for 24 to 48 hours with escalating energy or risky behavior
Severe medication side effects
Trouble breathing
Fainting or severe dizziness
High fever or severe muscle stiffness
Follow-up plan
Psychiatry or primary care appointment scheduling within 7 days when feasible
Crisis resources and local hotline information provided
Family or support person involvement for next 24 to 72 hours
References
Clinical guidelines and consensus sources
Guideline sources
American Psychiatric Association practice guidance on bipolar disorder
Diagnostic and treatment framework
Pharmacotherapy and psychotherapy principles
CANMAT and ISBD bipolar disorder guidelines
Acute mania recommendations
Bipolar depression and maintenance recommendations
NICE guideline on bipolar disorder
Assessment and long-term management pathways
Medication and psychological therapy recommendations
Emergency psychiatry consensus on acute agitation management
De-escalation and rapid tranquilization principles
Monitoring and restraint minimization principles
Evidence-based sources and tools
Evidence and tools
Young Mania Rating Scale (YMRS)
Severity tracking for mania
Treatment response monitoring
Columbia Suicide Severity Rating Scale (C-SSRS)
Standardized suicide risk assessment
Safety planning support
Local health system protocols
Involuntary hold criteria
ED agitation medication pathways
Update caution
Consult most recent local and specialty guidelines for dosing updates and pregnancy-specific recommendations
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.